Go Pro
→ Why I went to Mount Rushmore (From Stansberry Research) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Bellerophon Therapeutics, Inc. stock logo
BLPH
Bellerophon Therapeutics
$0.01
$0.02
$0.01
▼
$0.02
$147K0.7418,907 shsN/A
BPTSY
Biophytis
$0.25
$0.25
$0.00
▼
$2.08
$586K2.461,154 shs10 shs
IM Cannabis Corp. stock logo
IMCC
IM Cannabis
$4.23
+143.1%		$3.27
$1.55
▼
$77.10
$880K2.187,061 shs104.58 million shs
NKGen Biotech, Inc. stock logo
NKGN
NKGen Biotech
$0.00
$0.02
$0.00
▼
$0.33
$274K0.736,059 shsN/A
The Best Nuclear Energy Stocks to Buy Cover
The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Bellerophon Therapeutics, Inc. stock logo
BLPH
Bellerophon Therapeutics
0.00%0.00%0.00%0.00%0.00%
BPTSY
Biophytis
0.00%0.00%0.00%0.00%-87.50%
IM Cannabis Corp. stock logo
IMCC
IM Cannabis
0.00%+141.71%+23.58%-22.14%-92.58%
NKGen Biotech, Inc. stock logo
NKGN
NKGen Biotech
0.00%0.00%-58.82%-96.50%-98.42%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Bellerophon Therapeutics, Inc. stock logo
BLPH
Bellerophon Therapeutics
$0.01
$0.02
$0.01
▼
$0.02
$147K0.7418,907 shsN/A
BPTSY
Biophytis
$0.25
$0.25
$0.00
▼
$2.08
$586K2.461,154 shs10 shs
IM Cannabis Corp. stock logo
IMCC
IM Cannabis
$4.23
+143.1%		$3.27
$1.55
▼
$77.10
$880K2.187,061 shs104.58 million shs
NKGen Biotech, Inc. stock logo
NKGN
NKGen Biotech
$0.00
$0.02
$0.00
▼
$0.33
$274K0.736,059 shsN/A
The Best Nuclear Energy Stocks to Buy Cover
The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Bellerophon Therapeutics, Inc. stock logo
BLPH
Bellerophon Therapeutics
0.00%0.00%0.00%0.00%0.00%
BPTSY
Biophytis
0.00%0.00%0.00%0.00%-87.50%
IM Cannabis Corp. stock logo
IMCC
IM Cannabis
0.00%+141.71%+23.58%-22.14%-92.58%
NKGen Biotech, Inc. stock logo
NKGN
NKGen Biotech
0.00%0.00%-58.82%-96.50%-98.42%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Bellerophon Therapeutics, Inc. stock logo
BLPH
Bellerophon Therapeutics
0.00
N/AN/AN/A
BPTSY
Biophytis
0.00
N/AN/AN/A
IM Cannabis Corp. stock logo
IMCC
IM Cannabis
1.00
SellN/AN/A
NKGen Biotech, Inc. stock logo
NKGN
NKGen Biotech
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest BLPH, BPTSY, IMCC, and NKGN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/21/2026
IM Cannabis Corp. stock logo
IMCC
IM Cannabis
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
(Data available from 9/20/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Bellerophon Therapeutics, Inc. stock logo
BLPH
Bellerophon Therapeutics
$5.64M0.03N/AN/A$0.27 per share0.04
BPTSY
Biophytis
N/AN/AN/AN/A($16.18) per shareN/A
IM Cannabis Corp. stock logo
IMCC
IM Cannabis
$39.17M0.02N/AN/A($14.81) per share-0.29
NKGen Biotech, Inc. stock logo
NKGN
NKGen Biotech
N/AN/AN/AN/A($2.68) per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Bellerophon Therapeutics, Inc. stock logo
BLPH
Bellerophon Therapeutics
-$19.83M-$0.84N/AN/AN/AN/AN/AN/AN/A
BPTSY
Biophytis
-$18.43MN/AN/AN/AN/AN/AN/AN/AN/A
IM Cannabis Corp. stock logo
IMCC
IM Cannabis
-$8.10M-$60.66N/AN/AN/A-39.62%-585.96%-58.32%11/16/2026 (Estimated)
NKGen Biotech, Inc. stock logo
NKGN
NKGen Biotech
-$82.94M-$1.68N/AN/AN/AN/AN/A-479.36%N/A

Latest BLPH, BPTSY, IMCC, and NKGN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/13/2026Q2 2026
IM Cannabis Corp. stock logo
IMCC
IM Cannabis
N/A-$0.34N/A-$9.92N/A$5.34 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Bellerophon Therapeutics, Inc. stock logo
BLPH
Bellerophon Therapeutics
N/AN/AN/AN/AN/A
BPTSY
Biophytis
N/AN/AN/AN/AN/A
IM Cannabis Corp. stock logo
IMCC
IM Cannabis
N/AN/AN/AN/AN/A
NKGen Biotech, Inc. stock logo
NKGN
NKGen Biotech
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Bellerophon Therapeutics, Inc. stock logo
BLPH
Bellerophon Therapeutics
N/AN/AN/A
BPTSY
Biophytis
N/A
0.41
N/A
IM Cannabis Corp. stock logo
IMCC
IM Cannabis
N/A
0.56
0.46
NKGen Biotech, Inc. stock logo
NKGN
NKGen Biotech
N/A
0.02
0.02

Institutional Ownership

CompanyInstitutional Ownership
Bellerophon Therapeutics, Inc. stock logo
BLPH
Bellerophon Therapeutics
10.61%
BPTSY
Biophytis
0.05%
IM Cannabis Corp. stock logo
IMCC
IM Cannabis
7.68%
NKGen Biotech, Inc. stock logo
NKGN
NKGen Biotech
76.17%

Insider Ownership

CompanyInsider Ownership
Bellerophon Therapeutics, Inc. stock logo
BLPH
Bellerophon Therapeutics
5.20%
BPTSY
Biophytis
3.70%
IM Cannabis Corp. stock logo
IMCC
IM Cannabis
5.91%
NKGen Biotech, Inc. stock logo
NKGN
NKGen Biotech
10.36%
CompanyEmployeesShares OutstandingFree FloatOptionable
Bellerophon Therapeutics, Inc. stock logo
BLPH
Bellerophon Therapeutics
2012.23 million11.60 millionNo Data
BPTSY
Biophytis
302.35 million338,000N/A
IM Cannabis Corp. stock logo
IMCC
IM Cannabis
44210,000195,000Not Optionable
NKGen Biotech, Inc. stock logo
NKGN
NKGen Biotech
N/A130.60 million40.29 millionNot Optionable

Recent News About These Companies

NKGen Biotech To Present Troculeucel Program At Great Bay Cell And Gene Therapy Forum
September 16, 2026  |  rttnews.comhttps://www.rttnews.com/3691435/nkgen-biotech-to-present-troculeucel-program-at-great-bay-cell-and-gene-therapy-forum.aspx
NKGen Biotech to Present on Troculeucel for Neurodegenerative Diseases at 4th Great Bay Cell and Gene Therapy Forum
September 15, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/15/3362043/0/en/nkgen-biotech-to-present-on-troculeucel-for-neurodegenerative-diseases-at-4th-great-bay-cell-and-gene-therapy-forum.html
NKGen Biotech to Present on Potential of Troculeucel in Neurodegenerative Diseases at Biologics Manufacturing Korea 2026
September 10, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/10/3359470/0/en/nkgen-biotech-to-present-on-potential-of-troculeucel-in-neurodegenerative-diseases-at-biologics-manufacturing-korea-2026.html
NKGen Biotech to Present at the 2026 BIOCHINA Global Forum on Troculeucel’s Potential in Alzheimer’s Disease and Other Neurodegenerative Conditions
July 2, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/nkgen-biotech-to-present-at-the-2026-biochina-global-forum-on-troculeucel-s-potential-in-alzheimer-s-disease-and-other-neurodegenerative-conditions-1036293864
NKGen Biotech to Present at the 2026 BIOCHINA Global Forum on Troculeucel's Potential in Alzheimer's Disease and Other Neurodegenerative Conditions
July 2, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/02/3321294/0/en/nkgen-biotech-to-present-at-the-2026-biochina-global-forum-on-troculeucel-s-potential-in-alzheimer-s-disease-and-other-neurodegenerative-conditions.html
NKGen Biotech Expands Convertible Financing Through New Agreement
June 4, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/markets-news/Tipranks/2293059/nkgen-biotech-expands-convertible-financing-through-new-agreement/
NKGen Biotech Expands Clinical Trial Site Network for Alzheimer’s Disease Program Across U.S. to Improve Patient Access and Support Enrollment
May 19, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/nkgen-biotech-expands-clinical-trial-site-network-for-alzheimer-s-disease-program-across-u-s-to-improve-patient-access-and-support-enrollment-1036174943
NKGen Biotech Expands Clinical Trial Site Network for Alzheimer's Disease Program Across U.S. to Improve Patient Access and Support Enrollment
May 19, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/19/3297453/0/en/nkgen-biotech-expands-clinical-trial-site-network-for-alzheimer-s-disease-program-across-u-s-to-improve-patient-access-and-support-enrollment.html
NKGen Biotech to Present Troculeucel Mechanism Data in Alzheimer’s and Frontotemporal Dementia at the Neuroimmunology Drug Development Summit
April 10, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/sectors/healthcare/articles/nkgen-biotech-present-troculeucel-mechanism-120500934.html
NKGen Biotech to Present Troculeucel Mechanism Data in Alzheimer's and Frontotemporal Dementia at the Neuroimmunology Drug Development Summit
April 9, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/04/09/3270914/0/en/nkgen-biotech-to-present-troculeucel-mechanism-data-in-alzheimer-s-and-frontotemporal-dementia-at-the-neuroimmunology-drug-development-summit.html
NKGen Biotech Reports Combined Phase 1 Troculeucel Data Demonstrating Dose-Responsive Cognitive Improvements and Biomarker Correlations in Alzheimer’s Disease at AD/PD 2026™
March 23, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/nkgen-biotech-reports-combined-phase-1-troculeucel-data-demonstrating-dose-responsive-cognitive-improvements-and-biomarker-correlations-in-alzheimer-s-disease-at-ad-pd-2026-1035954017
NKGen Biotech Reports Combined Phase 1 Troculeucel Data Demonstrating Dose-Responsive Cognitive Improvements and Biomarker Correlations in Alzheimer's Disease at AD/PD 2026™
March 23, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/03/23/3260349/0/en/nkgen-biotech-reports-combined-phase-1-troculeucel-data-demonstrating-dose-responsive-cognitive-improvements-and-biomarker-correlations-in-alzheimer-s-disease-at-ad-pd-2026.html
NKGen Biotech to Present Integrated Phase 1 Clinical and Biomarker Analyses for Troculeucel in Alzheimer’s Disease at AD/PD™ 2026
March 10, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/nkgen-biotech-to-present-integrated-phase-1-clinical-and-biomarker-analyses-for-troculeucel-in-alzheimer-s-disease-at-ad-pd-2026-1035914027
NKGen Biotech to Present Integrated Phase 1 Clinical and Biomarker Analyses for Troculeucel in Alzheimer's Disease at AD/PD™ 2026
March 10, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/03/10/3252766/0/en/nkgen-biotech-to-present-integrated-phase-1-clinical-and-biomarker-analyses-for-troculeucel-in-alzheimer-s-disease-at-ad-pd-2026.html
NKGen Biotech Names Leading Dementia Expert Bruce L. Miller, M.D. to Scientific Advisory Board
January 22, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/nkgen-biotech-names-leading-dementia-expert-bruce-l-miller-m-d-to-scientific-advisory-board-1035736424
NKGen Biotech Names Leading Dementia Expert Bruce L. Miller, M.D.
January 22, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/01/22/3223710/0/en/nkgen-biotech-names-leading-dementia-expert-bruce-l-miller-m-d-to-scientific-advisory-board.html
NKGen Biotech issues statement on NKGen Korea board appointments
December 3, 2025  |  msn.comhttps://www.msn.com/en-us/money/executive-leadership-and-management/nkgen-biotech-issues-statement-on-nkgen-korea-board-appointments/ar-AA1REczu
NKGen Biotech, Inc. Issues Statement on Recent Board Appointments at Majority-Owned Korean Affiliate NKGen Korea Co., Ltd.
December 3, 2025  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/nkgen-biotech-inc-issues-statement-on-recent-board-appointments-at-majority-owned-korean-affiliate-nkgen-korea-co-ltd-1035613999
NKGen Biotech Provides Clarification on Quotation Display and Trading Status on the OTC Expert Market
October 9, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/10/09/3164110/0/en/NKGen-Biotech-Provides-Clarification-on-Quotation-Display-and-Trading-Status-on-the-OTC-Expert-Market.html
NKGen Biotech to Present on the Use of Troculeucel for Neurodegenerative Diseases at the XXVII World Congress of Neurology
October 6, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/10/06/3161688/0/en/NKGen-Biotech-to-Present-on-the-Use-of-Troculeucel-for-Neurodegenerative-Diseases-at-the-XXVII-World-Congress-of-Neurology.html

New MarketBeat Followers Over Time

Media Sentiment Over Time

Bellerophon Therapeutics stock logo

Bellerophon Therapeutics NASDAQ:BLPH

Bellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its primary product is INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension. The company engages in the development of INOpulse, which is in Phase 3 clinical trial for the treatment of pulmonary hypertension associated with fibrotic interstitial lung disease; which has completed Phase 2a clinical trial for pulmonary hypertension associated with chronic obstructive pulmonary disease; and that has completed Phase 2 dose escalation stage for pulmonary hypertension associated with sarcoidosis, as well as for chronic thromboembolic pulmonary hypertension and pulmonary hypertension associated with pulmonary edema from high altitude sickness. The company was formerly known as Ikaria Development LLC and changed its name to Bellerophon Therapeutics, Inc. in January 2014. Bellerophon Therapeutics, Inc. was founded in 2009 and is headquartered in Warren, New Jersey.

Biophytis NASDAQ:BPTSY

$0.25 0.00 (0.00%)
As of 09/18/2026

Biophytis S.A., a clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients suffering from age-related diseases. Its therapeutics focuses on targeting and activating key biological resilience pathways that could protect against and counteract the effects of the multiple biological and environmental stresses including inflammatory, oxidative, metabolic, and viral stresses that lead to age-related diseases. The company's lead drug candidate is Sarconeos (BIO101), an orally administered small molecule in development for the treatment of neuromuscular diseases, including sarcopenia and Duchenne muscular dystrophy (DMD), as well as in Phase 2/3 clinical study for the treatment of severe respiratory failure in patients suffering from COVID-19. It also develops Macuneos (BIO201), an orally administered small molecule for the treatment of retinal diseases, including dry age-related macular degeneration (AMD) and Stargardt disease. Biophytis SA has a collaboration agreement with AFM-Telethon for the development of its Sarconeos (BIO101) for the treatment of DMD. The company was incorporated in 2006 and is headquartered in Paris, France.

IM Cannabis stock logo

IM Cannabis NASDAQ:IMCC

$4.23 +2.49 (+143.10%)
Closing price 09/18/2026 04:00 PM Eastern
Extended Trading
$3.17 -1.06 (-25.13%)
As of 09/18/2026 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

IM Cannabis Corp. engages in breeding, growing, and supply of medical cannabis products in Israel and Germany. It offers cannabis flowers and strain-specific cannabis extracts under the IMC brand; and dried flower, pre-rolls, minis, and full spectrum extracts offerings under the WAGNERS and BLKMKT brands. The company serves medical patients. IM Cannabis Corp. is headquartered in Tel Aviv, Israel.

NKGen Biotech stock logo

NKGen Biotech NYSE:NKGN

$0.0021 0.00 (0.00%)
As of 09/18/2026

NKGen Biotech, Inc. operates as a clinical-stage biotechnology company that focuses on the development and commercialization of autologous, allogeneic, and CAR-NK natural killer cell therapies. It develops SNK01, an autologous NK cell therapy; and SNK02, an allogeneic NK cell therapy, which are in Phase 1 clinical trials. The company was founded in 2017 and is based in Santa Ana, California.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas